Literature DB >> 2322993

Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.

W J van der Vijgh1, P A Maessen, H M Pinedo.   

Abstract

Epidoxorubicin, a stereoisomer of doxorubicin, shows comparable antitumor activity but diminished cardiotoxicity compared with the latter. To find a pharmacokinetic basis for the observed difference in cardiotoxicity between the drugs, concentrations of doxorubicin, epidoxorubicin and all known metabolites were measured in the plasma, heart and tumor tissue of BALB/c mice bearing colon-26 tumors. Both drugs were injected at the same dose (10 mg/kg) as an i.v. bolus. Plasma, heart and tumor samples were obtained from two mice sacrificed at regular intervals over 48 h. Plasma and tissue extracts were analyzed by HPLC with fluorescence detection. The parent compounds and the two 7d-aglycones were present in all three compartments, whereas doxorubicinol (Aol) and epidoxorubicinol (Eol) could only be detected in the plasma and heart. Half-lives and AUCs of doxorubicin and its metabolites were higher than the corresponding values for epidoxorubicin and its metabolites in all three compartments.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322993     DOI: 10.1007/bf02940286

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.

Authors:  F M Torti; M M Bristow; B L Lum; S K Carter; A E Howes; D A Aston; B W Brown; J F Hannigan; F J Meyers; E P Mitchell
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

Review 2.  Metabolism and reactions of quinoid anticancer agents.

Authors:  G Powis
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

3.  Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.

Authors:  T W Sweatman; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.

Authors:  F Arcamone; M Lazzati; G P Vicario; G Zini
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Experimental systemic toxicology of 4'-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent.

Authors:  C Bertazzoli; C Rovero; L Ballerini; B Lux; F Balconi; V Antongiovanni; U Magrini
Journal:  Toxicol Appl Pharmacol       Date:  1985-07       Impact factor: 4.219

6.  Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.

Authors:  K Mross; P Maessen; W J van der Vijgh; H Gall; E Boven; H M Pinedo
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

7.  General and cardiac toxicity of adriamycinol in rats.

Authors:  R Danesi; M Del Tacca; P Della Torre; C Bernardini
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480

8.  Hepatic metabolism of doxorubicin in mice and rats.

Authors:  P Vrignaud; D Londos-Gagliardi; J Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

9.  Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

Authors:  R D Olson; P S Mushlin; D E Brenner; S Fleischer; B J Cusack; B K Chang; R J Boucek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

10.  Metabolism of adriamycin in hepatocytes isolated from the rat and the rabbit.

Authors:  D A Gewirtz; S Yanovich
Journal:  Biochem Pharmacol       Date:  1987-06-01       Impact factor: 5.858

View more
  15 in total

1.  Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase.

Authors:  Michael J Mihm; Fushun Yu; David M Weinstein; Peter J Reiser; John Anthony Bauer
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitro.

Authors:  D Bartkowiak; J Hemmer; E Röttinger
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.

Authors:  Saisudha Koka; Anindita Das; Shu-Guang Zhu; David Durrant; Lei Xi; Rakesh C Kukreja
Journal:  J Pharmacol Exp Ther       Date:  2010-06-11       Impact factor: 4.030

4.  Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro.

Authors:  Partha Mukhopadhyay; Mohanraj Rajesh; Sándor Bátkai; Yoshihiro Kashiwaya; György Haskó; Lucas Liaudet; Csaba Szabó; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

6.  Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice.

Authors:  J de Jong; I Klein; A Bast; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.

Authors:  Daniel R Schwartz; Erika R Briggs; Mohammed Qatanani; Heloisa Sawaya; Igal A Sebag; Michael H Picard; Marielle Scherrer-Crosbie; Mitchell A Lazar
Journal:  Endocrinology       Date:  2013-08-27       Impact factor: 4.736

8.  Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

Authors:  S A van Acker; K Kramer; J A Grimbergen; D J van den Berg; W J van der Vijgh; A Bast
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

Review 9.  Clinical pharmacokinetics of epirubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

10.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.